Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial.

Jing HeRuijun ZhangMiao ShaoXiaozhen ZhaoMiao MiaoJiali ChenJiajia LiuXiaoying ZhangXia ZhangYuebo JinYu WangShilei ZhangLei ZhuAlexander JacobRulin JiaXujie YouXue LiChun LiYunshan ZhouYue YangHua YeYanying LiuYin SuNan ShenJessy AlexanderJianping GuoJulian AmbrusXin LinDi YuXiaolin SunZhanguo Li

Published in: Annals of the rheumatic diseases (2019)

ClinicalTrials.gov Registries (NCT02465580 and NCT02932137).

Keyphrases

double blind
placebo controlled
systemic lupus erythematosus
low dose
clinical trial
study protocol
phase iii
phase ii
high dose
open label
disease activity
randomized controlled trial
combination therapy